Cold Genesys, Inc. is a privately-held, clinical-stage oncolytic viral immunotherapy company with its lead product CG0070 now in an integrated Phase II/III clinical trial for bladder cancer. CG0070 is a conditionally replication-competent adenovirus, containing an E2F promoter in the viral E1A region that drives the expression of GM-CSF. CGI also has developed n-dodecyl-D-maltoside to specifically enhance viral transduction in cancer cells. CG0070 was previously tested in a Phase I/II trial of 35 patients with non-muscle invasive bladder cancer in 2008.